NASDAQ:ALLO Allogene Therapeutics (ALLO) Stock Price, News & Analysis $2.00 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.00 0.00 (0.00%) As of 05/22/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Allogene Therapeutics Stock (NASDAQ:ALLO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Allogene Therapeutics alerts:Sign Up Key Stats Today's Range$1.96▼$2.0550-Day Range$1.89▼$3.0452-Week Range$0.98▼$4.46Volume4.12 million shsAverage Volume6.31 million shsMarket Capitalization$690.30 millionP/E RatioN/ADividend YieldN/APrice Target$8.52Consensus RatingModerate Buy Company Overview Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance. The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers. Lead programs include ALLO-715, an anti-BCMA therapy for multiple myeloma, and ALLO-501, which targets CD19 for non-Hodgkin lymphoma and other B-cell malignancies. Allogene applies proprietary TALEN gene-editing to disrupt the endogenous T-cell receptor and other genes, reducing the risk of graft-versus-host disease and enabling repeat dosing possibilities. Headquartered in South San Francisco, California, Allogene collaborates with global partners to advance its off-the-shelf portfolio. A strategic alliance with Servier grants the European-based pharmaceutical company exclusive ex-U.S. rights to develop and commercialize select Allogene candidates. This partnership supports clinical development across North America, Europe and other key oncology markets. Founded in 2017 as a spin-out from Kite Pharma, Allogene Therapeutics went public in 2020 to support the rapid advancement of its clinical programs. The company is led by President and Chief Executive Officer David Chang, whose background spans immuno-oncology research and strategic biotech leadership. Under his direction, Allogene aims to establish allogeneic CAR T as a new standard in cell-based cancer treatment.AI Generated. May Contain Errors. Read More Allogene Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreALLO MarketRank™: Allogene Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 500th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingAllogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 1 strong buy rating, 8 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialAllogene Therapeutics has a consensus price target of $8.52, representing about 326.1% upside from its current price of $2.00.Amount of Analyst CoverageAllogene Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Allogene Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Allogene Therapeutics are expected to decrease in the coming year, from ($0.72) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 2.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Allogene Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.34% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 3.71, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allogene Therapeutics has recently increased by 1.31%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 12 people have searched for ALLO on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.MarketBeat Follows11 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 22% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $177,771.00 in company stock.Percentage Held by Insiders13.20% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.63% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Allogene Therapeutics' insider trading history. Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALLO Stock News HeadlinesAllogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165MMay 14, 2026 | seekingalpha.comBig Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category LeadersMay 14, 2026 | 247wallst.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.May 25 at 1:00 AM | Behind the Markets (Ad)Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comAllogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and ...May 14, 2026 | finance.yahoo.comAllogene Therapeutics Q1 2026 Earnings Call TranscriptMay 14, 2026 | finance.yahoo.comAllogene Therapeutics ends China cell therapy deal with OverlandMay 13, 2026 | reuters.comAllogene Therapeutics Reports First Quarter 2026 Financial Results and Business UpdateMay 13, 2026 | globenewswire.comSee More Headlines ALLO Stock Analysis - Frequently Asked Questions How have ALLO shares performed this year? Allogene Therapeutics' stock was trading at $1.37 at the beginning of 2026. Since then, ALLO stock has increased by 46.0% and is now trading at $2.00. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. Read the conference call transcript. When did Allogene Therapeutics IPO? Allogene Therapeutics (ALLO) raised $306 million in an initial public offering on Thursday, October 11th 2018. The company issued 18,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO. Who are Allogene Therapeutics' major shareholders? Allogene Therapeutics' top institutional investors include Candriam S.C.A. (1.22%), Renaissance Technologies LLC (0.87%), Bank of America Corp DE (0.87%) and Dimensional Fund Advisors LP (0.49%). Insiders that own company stock include David D Chang, Arie Belldegrun, Geoffrey M Parker, Zachary Roberts, Earl Martin Douglas, Franz B Humer, Timothy L Moore, Benjamin Machinas Beneski, Annie Yoshiyama and Stephen Mayo. View institutional ownership trends. How do I buy shares of Allogene Therapeutics? Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allogene Therapeutics investors own include Waste Connections (WCN), American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/13/2026Today5/25/2026AGM 20266/18/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ALLO's financial health is in the Green zone, according to TradeSmith. ALLO has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALLO CIK1737287 Webwww.allogene.com Phone(650) 457-2700FaxN/AEmployees310Year Founded2018Price Target and Rating Average Price Target for Allogene Therapeutics$8.52 High Price Target$14.00 Low Price Target$3.85 Potential Upside/Downside+326.1%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$190.89 million Net MarginsN/A Pretax MarginN/A Return on Equity-56.45% Return on Assets-40.36% Debt Debt-to-Equity RatioN/A Current Ratio9.65 Quick Ratio9.65 Sales & Book Value Annual Sales$20 thousand Price / Sales34,515.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book2.47Miscellaneous Outstanding Shares345,150,000Free Float299,595,000Market Cap$690.30 million OptionableOptionable Beta0.46 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ALLO) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
